Back to Agenda
Session 7: Case Study: COVID R&D Alliance, RWE Informing COVID-19 Drug Development and Closing Remarks
Session Chair(s)
Brian Bradbury, DrSc, MA
Vice President, Center for Observational Research
Amgen, United States
Marni Hall, PhD, MPH
VP & GM, Global Regulatory Science and Strategy
IQVIA, United States
This session provides an introduction to the COVID R&D Alliance and how the use of RWE is assisting in the design of platforms trials and providing evidence regarding the natural history of disease for patients diagnosed with COVID-19. Emphasis will be placed on the value of coordinated and collaborative engagement across manufactures and the lessons learned from this effort.
Learning Objective : - Describe the COVID R&D Alliance and the collaborative approach that manufacturers are taking to accelerate the testing of repurposed medicines as potential treatment
- Discuss ongoing R&D Alliance RWE studies designed to better inform on the natural history of disease and the safety of treatments
- Apply lessons learned from COVID R&D Alliance RWE collaborations to research efforts in the post-COVID environment
Speaker(s)
Speaker: Anne Heatherington, PhD
Senior Vice President, Head of Data Sciences Institute
Takeda Pharmaceuticals, United States
Speaker: Cathy W Critchlow, PhD, MSc
Vice President, R&D Data Strategy
Amgen, Inc, United States
Speaker: Ying Bao, DrSc, MD
Senior Director, Center for Observational Research and Data Science
Bristol Myers Squibb, United States
Closing Remarks: Brian Bradbury, DrSc, MA
Vice President, Center for Observational Research
Amgen, United States
Have an account?